These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 8577632

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK, Sause RB, Zacker C.
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [Abstract] [Full Text] [Related]

  • 3. Overview of cost-consequence modeling in outcomes research.
    Stergachis A.
    Pharmacotherapy; 1995 Dec; 15(5 Pt 2):40S-42S. PubMed ID: 8577629
    [Abstract] [Full Text] [Related]

  • 4. The case for a value-based formulary: striving for total lowest net cost.
    Weart W, Bauman GR.
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ.
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Managing drug costs: the perception of managed care pharmacy directors.
    Litton LM, Sisk FA, Akins ME.
    Am J Manag Care; 2000 Jul; 6(7):805-14. PubMed ID: 11067377
    [Abstract] [Full Text] [Related]

  • 8. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV, Wright-Etter PJ.
    Manag Care Q; 2002 Jul; 10(3):21-31. PubMed ID: 12476662
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM, Ereshefsky L.
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach.
    Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Atherly D.
    Am J Manag Care; 1999 Mar; 5(3):277-85. PubMed ID: 10351024
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Mar; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. How should treatment costs impact on physician's decisions?
    Neymark N.
    Acta Otorhinolaryngol Belg; 1999 Mar; 53(3):289-92. PubMed ID: 10635410
    [Abstract] [Full Text] [Related]

  • 20. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.